CRISPR-Cas9 and Genomic Technologies in Precision Medicine: Transforming Disease Diagnosis, Therapy, and Personalized Treatment

Arshpreet Kaur Kohli[1], Raghu Raja Mehra[2]

Department of Information Technology, Invictus International School, Amritsar, India
Email: *arshpreetkaur[at]invictusschool.edu.in*

Department of Information Technology, Invictus International School, Amritsar, India
Email: *raghu[at]invictusschool.edu.in*

Abstract: ***This review examines the integration of CRISPR-Cas9 with genomic technologies in advancing precision medicine. It outlines the scientific basis of CRISPR systems and their convergence with next-generation sequencing, bioinformatics, and artificial intelligence. The study synthesizes current literature across oncology, inherited disorders, infectious diseases, and neurological conditions, and compares emerging gene-editing platforms including base and prime editing. Evidence from recent clinical studies, including CRISPR-based therapies, demonstrates significant progress toward targeted and curative interventions. Key challenges such as off-target effects, ethical concerns, and data inequity are also analyzed. The review concludes that genomic technologies are shifting medicine toward proactive, genotype-driven care, though further work is needed to ensure safety, accessibility, and regulatory clarity.***

Keywords: CRISPR-Cas9, Genomics, Precision Medicine, Gene Editing, Next-Generation Sequencing, Personalized Therapy, Base Editing, Oncogenomics, Bioinformatics, Epigenomics, CRISPR Therapeutics, Genome Editing Safety, Clinical Genomics Implementation.

1. Introduction

Modern medicine stands at a remarkable inflection point. For centuries, clinical practice operated on a population-level logic: drugs and therapies were developed for the average patient, dosing was standardized, and diagnosis relied largely on observable symptoms rather than molecular determinants. The sequencing of the human genome in 2003 marked the beginning of a new era, one in which the molecular blueprint of individual patients could, in principle, guide every aspect of disease prevention, diagnosis, and treatment.

Precision medicine, also referred to as personalized medicine or genomic medicine, is the clinical embodiment of this shift. It aims to deliver the right treatment, to the right patient, at the right time, based on each individual's genetic, proteomic, and environmental profile. Central to this vision are technologies that can read, interpret, and increasingly write the genomic code: next-generation sequencing (NGS) platforms that decode entire genomes in hours; bioinformatics pipelines that translate billions of base pairs into actionable clinical insights; and gene-editing tools, most notably CRISPR-Cas9 that allow targeted modification of the human genome with unprecedented precision.

2. Methods

This study is a narrative review of the current scientific and clinical literature on CRISPR-Cas9 and genomic technologies in precision medicine. A systematic search was conducted across the following electronic databases: PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. Search keywords included: “CRISPR-Cas9,” “genomic medicine,” “precision medicine,” “gene editing,” “next-generation sequencing,” “base editing,” “prime editing,” “pharmacogenomics,” and “liquid biopsy.” The search was limited to publications from 2010 to 2024, with seminal pre-2010 studies included where foundational to the field. Inclusion criteria required peer-reviewed articles, clinical trial reports, and authoritative database sources (e.g., FDA, NHGRI, NIH) directly relevant to genomic technologies or CRISPR applications in a clinical or translational context. Review articles, editorials, and non-peer-reviewed sources were excluded unless representing consensus guidelines or regulatory documentation. A total of 20 high-impact references were selected for synthesis. The review follows a narrative structure, synthesizing findings across thematic domains: mechanism, diagnostics, therapeutics, comparative platforms, ethical challenges, and future directions.

3. Literature Review

The scientific literature underpinning CRISPR and genomic medicine has expanded exponentially since the landmark publications of the early 2010s. Jinek et al. (2012) published the foundational Science paper demonstrating CRISPR-Cas9 as a programmable RNA-guided endonuclease capable of site-specific DNA cleavage, establishing the molecular basis for all subsequent gene-editing applications. Cong et al. (2013) and Mali et al. (2013) concurrently demonstrated CRISPR-Cas9-mediated genome editing in human cells, marking the transition from biochemical tool to biomedical instrument.

The clinical translation of CRISPR accelerated with the work of Frangoul et al. (2021), published in the New England Journal of Medicine, reporting the first clinical trial results of CRISPR-based therapy (CTX001) in patients with sickle cell disease and transfusion-dependent beta-thalassemia. Both patients achieved near-complete remission following a single treatment, validating the therapeutic potential of somatic genome editing in hematopoietic stem cells.



Figure 1: Key Milestones in CRISPR & Genomic Medicine (2003–2024)
Source: Compiled from Nature (2012, 2021), NEJM (2021), FDA Approvals Database, and GRAIL publications

4. Genomic Medicine: Overview and Core Challenges

1) The Genomic Medicine Pipeline

Precision medicine follows an integrated pipeline spanning genomic data acquisition, variant interpretation, clinical decision support, therapeutic intervention, and outcomes monitoring. Figure 1 illustrates the conventional genomic medicine workflow from patient sample to therapeutic action.

Figure 2: Genomic Medicine Pipeline- From Sample to Therapy
Source: Adapted from NIH National Human Genome Research Institute (NHGRI) Framework

2) Core Challenges in Conventional Medicine

Traditional medicine faces deep structural limitations when confronted with the complexity of human genomic variation. First, population-level drug dosing ignores pharmacogenomic variability: up to 30% of patients metabolize common drugs aberrantly due to genetic polymorphisms in CYP450 enzymes, leading to adverse events or therapeutic failure. Second, late-stage cancer diagnoses occur because genomic biomarkers are not routinely screened at early stages. Third, inherited monogenic disorders such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell disease remain incurable under conventional pharmacological approaches.



Figure 3: Leading Causes of Clinical Drug Trial Failure
Source: DiMasi et al. (2016), Hay et al. (2014) Precision genomics directly addresses the top two failure categories

5. Comparative Analysis: Traditional vs. Genomics-Driven Medicine

The table below provides a structured comparison of key parameters between traditional medical approaches and genomics-driven precision medicine, illustrating the transformative impact of genomic technologies at each stage of clinical practice.

Table I: Traditional Medicine vs. Genomics-Driven Precision Medicine

Parameter	Traditional Medicine	Genomics-Driven Precision Medicine
Diagnosis Basis	Symptoms, imaging, biomarkers	Whole-genome / transcriptomic profiling
Drug Selection	Trial-and-error, population averages	Pharmacogenomic-guided, genotype-specific
Cancer Treatment	Chemotherapy by tumor site	Mutation-targeted therapy (e.g., EGFR, BRCA)
Inherited Disease	Symptomatic management	CRISPR-based gene correction at source
Pathogen Detection	Culture / serology (days)	Metagenomic sequencing (hours)
Drug Toxicity	Identified post-market	Predicted by PGx profiling pre-prescription
Clinical Trials	Broad eligibility criteria	Biomarker-stratified, genomic eligibility
Data Utilization	Clinical records, siloed	Multi-omics integrated with EHR and AI

Source: Ginsburg & Phillips (2018), NHGRI (2021), Frangoul et al. (2021)

6. Genomic Technologies in Precision Medicine

a) CRISPR-Cas9: Mechanism and Clinical Applications

CRISPR-Cas9 operates through a two-component system: a single guide RNA (sgRNA) that directs the Cas9 endonuclease to a complementary genomic target sequence, where Cas9 introduces a double-strand break (DSB). The cell's native DNA repair pathways (non-homologous end joining (NHEJ) or homology-directed repair (HDR)) then either disrupt (knock out) or precisely correct the targeted gene sequence. This programmability, achievable by simply redesigning the 20-nucleotide guide sequence, distinguishes CRISPR-Cas9 from earlier editing platforms and has enabled its rapid deployment across therapeutic areas. Figure 2 illustrates the molecular mechanism of CRISPR-Cas9 action.



Figure 4: CRISPR-Cas9 Mechanism- Guide RNA, Cas9 Cleavage & DNA Repair Pathways

Source: Adapted from Jinek et al. (2012) Science; Cong et al. (2013) Science

In hematology, CRISPR-based editing of BCL11A enhancer elements reactivates fetal hemoglobin production in sickle cell disease and beta-thalassemia patients, addressing the genetic root cause of these disorders. In oncology, CRISPR is used to engineer chimeric antigen receptor (CAR) T cells by knocking out immunosuppressive checkpoints. In infectious disease, CRISPR-based diagnostics (SHERLOCK, DETECTR) provide rapid, field-deployable nucleic acid detection for pathogens including SARS-CoV-2.

b) Next-Generation Sequencing (NGS) in Diagnostics

NGS platforms have democratized genomic analysis by reducing whole-genome sequencing costs from $3 billion (Human Genome Project, 2003) to under $200 in 2024. Figure 6 charts this dramatic cost trajectory, which mirrors Moore's Law but at a steeper decline, and has been the single most enabling factor in the transition from research genomics to clinical genomics.

Figure 5: Cost of Whole Genome Sequencing (2003–2024)

Source: NHGRI Genome Sequencing Cost Data (2024)- https://www.genome.gov/sequencingcosts

c) Base Editing and Prime Editing: Next-Generation Precision

Base editing, developed by David Liu's laboratory at Harvard, enables direct chemical conversion of one DNA base to another (C-to-T or A-to-G) without introducing double-strand breaks. This approach dramatically reduces the risk of unintended insertions and deletions (indels), a key safety concern with first-generation CRISPR-Cas9. Prime editing, also from Liu's group, uses a reverse transcriptase-Cas9 fusion to write new genetic sequences directly into the genome using an engineered pegRNA, enabling all 12 types of point mutations, small insertions, and small deletions with greater precision.

d) Pharmacogenomics: Genotype-Guided Prescribing

Pharmacogenomics (PGx) studies how genetic variation influences drug response. The FDA has issued pharmacogenomic labeling for over 250 drugs, covering metabolism (CYP2D6, CYP2C19), transport (ABCB1), and target (VKORC1 for warfarin) genes. Clinical implementation of PGx testing has been demonstrated to reduce adverse drug reactions by up to 30% in prospective trials. The CPIC guidelines consortium provides curated evidence-based dosing recommendations for PGx-drug pairs.

7. Leading Genomic Medicine Platforms and Tools

The table below profiles the most prominent genomic medicine platforms currently deployed in clinical and research settings.

Table II: Key Platforms in Genomic Medicine and CRISPR-Based Therapy

Platform / Tool	Developer	Primary Application	Notable Achievement
CTX001 (Casgevy)	Vertex / CRISPR Therapeutics	Sickle cell & beta-thalassemia	First FDA-approved CRISPR therapy (2023)
CRISPR-CAR-T	Intellia Therapeutics	Cancer immunotherapy	Persistent CRISPR T-cells in solid tumors
SHERLOCK	Sherlock Biosciences / MIT	CRISPR-based diagnostics	COVID-19 detection in 30 minutes
Illumina NovaSeq X	Illumina	Whole-genome sequencing	Sub-$200 WGS per sample
Guardant360	Guardant Health	Liquid biopsy / ctDNA	Validated in 50+ tumor types
GRAIL Galleri	GRAIL Inc.	Multi-cancer early detection	Detects 50+ cancers from single blood draw
FoundationOne CDx	Foundation Medicine	Tumor genomic profiling	FDA-approved comprehensive cancer panel
Tempus AI Platform	Tempus	Oncogenomics + AI	Largest real-world clinical-genomic database

Source: FDA approvals database, company publications, Nature Medicine (2023), NEJM (2021)

8. Gene Editing Technologies: A Comparative Review

A broad spectrum of gene-editing technologies exists beyond CRISPR-Cas9. Figure 3 presents a visual comparison of the three most critical performance dimensions- on-target specificity, ease of design, and relative cost- while Table III provides a detailed qualitative comparison.



Figure 6: Comparative Performance of Gene Editing Technologies
Source: Anzalone et al. (2019), Komor et al. (2016), Joung & Sander (2013), Kim & Kim (2014)

Table III: Comparative Analysis of Gene Editing Technologies

Technology	Mechanism	Advantages	Limitations
CRISPR-Cas9	RNA-guided DSB endonuclease	Highly programmable, low cost, scalable	Off-target edits, immune response
Base Editing (BE4)	Cytosine/adenine base deaminase	No DSB, fewer indels, precise	Limited edit types, PAM constraints
Prime Editing	pegRNA + reverse transcriptase	All 12 point mutations, no DSB	Lower efficiency, large cargo size
ZFNs	Engineered zinc-finger proteins	No guide RNA needed	Complex design, expensive
TALENs	TALE-FokI fusion proteins	High specificity per nucleotide	Large protein size, difficult delivery
Epigenome Editing (dCas9)	Catalytically dead Cas9 + effector	Gene regulation without editing DNA	Transient effects, delivery challenges

Source: Anzalone et al. (2019), Komor et al. (2016), Joung & Sander (2013)

9. Proposed Integrated Genomic Precision Medicine Framework

Based on our review of existing literature and clinical practice, we propose an integrated genomic precision medicine framework. This framework replaces reactive, population-based treatment with a proactive, iterative, data-driven clinical workflow anchored on genomic profiling at every stage of care. Figure 8 illustrates the proposed framework architecture.



Figure 7: Proposed Integrated Genomic Precision Medicine Framework
Source: Authors' conceptual framework based on synthesized literature review

Framework Components

The proposed framework begins with preemptive genomic profiling at the point of patient enrollment- ideally before disease onset- to establish a genomic baseline. AI-driven variant interpretation pipelines classify germline and somatic variants by clinical significance, integrating evidence from curated databases (ClinVar, OMIM, OncoKB). Pharmacogenomic-guided prescribing modules query the patient's PGx profile at every drug prescription event. For patients with correctable mutations, CRISPR-based gene therapy options are evaluated under a regulatory-compliant clinical pathway. Real-time liquid biopsy monitoring tracks disease trajectory and treatment response.

10. Advantages and Challenges of Genomic Technologies in Precision Medicine

Table IV: Advantages vs. Challenges of Genomic Precision Medicine

Advantages	Challenges / Risks
Curative potential for mono-genic diseases	Off-target CRISPR edits and genomic instability
Early cancer detection via liquid biopsy	High cost and limited global accessi-bility
Pharmacogenomics reduces adverse drug reactions	Data privacy and genomic infor-mation security
Targeted cancer therapy improves survival	Ethical concerns over germline edit-ing
CRISPR diagnostics enable rapid pathogen ID	Regulatory uncertainty for novel gene therapies
Personalized dosing maxim-izes drug efficacy	Limited genomic databases for non-European populations
Eliminates years of ineffec-tive treatment	Mosaicism and incomplete editing efficiency
Accelerated rare disease diagnosis	Long-term safety data still accumulat-ing

Source: Authors' synthesis based on reviewed literature

a) Key Advantages

The most transformative advantage of genomic precision medicine is its curative rather than merely palliative potential for single-gene disorders. The FDA approval of Casgevy in 2023 for sickle cell disease represents the first realized CRISPR cure: patients who previously required lifelong blood transfusions are achieving functional remission after a single treatment. Figure 7 shows the clinical efficacy achieved across key genomic therapeutic areas.



Figure 8: Efficacy of Genomic Precision Medicine Across Key Therapeutic Areas

Source: Frangoul et al. (2021) NEJM; Mok et al. (2009) NEJM; Reinert et al. (2022) JAMA Oncology; Turner et al. (2021) NEJM

b) Key Challenges

The primary technical challenge facing CRISPR therapeutics remains off-target editing, unintended modifications at non-target genomic sites that could disrupt tumor suppressor genes or activate oncogenes. Advanced specificity tools (high-fidelity Cas9 variants, Cas12a, paired nickases) are being deployed to characterize and minimize this risk. Germline editing raises profound ethical questions about consent, eugenics, and equity, concerns heightened by the rogue CRISPR baby experiment in China in 2018. Data equity is an emerging systemic challenge: most genomic reference databases are derived predominantly from European-ancestry populations, limiting the accuracy of variant interpretation for African, Asian, and South Asian patients.

11. Notable Case Studies

1) Casgevy: The First CRISPR Cure

In November 2023, the FDA approved Casgevy (exagamglogene autotemcel, exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease — the world's first approved CRISPR-based therapeutic. The therapy works by harvesting a patient's own hematopoietic stem cells, editing them ex vivo with CRISPR-Cas9 to disrupt the BCL11A enhancer and reactivate fetal hemoglobin (HbF) production, and reinfusing the corrected cells. In the pivotal CLIMB-SCD-121 trial, 28 of 29 patients (97%) were free of vaso-occlusive crises for at least 12 months post-treatment.

2) GRAIL Galleri Multi-Cancer Early Detection

GRAIL's Galleri test represents a paradigm shift in cancer screening. Using a single blood draw, the assay analyzes methylation patterns in cell-free DNA to detect over 50 cancer types simultaneously. In the PATHFINDER study published in 2022, Galleri demonstrated cancer detection in 1.4% of screened individuals, with a false positive rate of less than 1%. The test predicts not only whether cancer is present but its tissue of origin, guiding clinical investigation.

3) SHERLOCK CRISPR Diagnostics for COVID-19

During the COVID-19 pandemic, SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), developed at MIT by Feng Zhang's laboratory, leveraged the collateral cleavage activity of Cas13 to generate a fluorescent signal in the presence of target viral RNA. The SHERLOCK test for SARS-CoV-2 achieved sensitivity and specificity comparable to RT-PCR in under 30 minutes without requiring sophisticated laboratory equipment. In 2020, the FDA granted emergency use authorization to a SHERLOCK-based SARS-CoV-2 test, marking the first approved CRISPR diagnostic.

4) Liquid Biopsy in Colorectal Cancer

A landmark 2022 study published in Nature Medicine demonstrated that ctDNA detection after surgical resection of Stage II colorectal cancer predicted relapse with a lead time of 8.7 months before clinical detection. Patients with detectable post-surgical ctDNA who received adjuvant chemotherapy had significantly improved survival outcomes compared to untreated ctDNA-positive patients. This study exemplifies the clinical utility of liquid biopsy in guiding adjuvant therapy decisions.

12. Future Scope and Research Directions

Table V: Future Directions in Genomic Precision Medicine

Future Direction	Description	Expected Impact
In Vivo CRISPR Delivery	LNP and viral vectors delivering CRISPR directly to liver, muscle, CNS	Expand beyond ex vivo hematology applications
AI-Guided Guide RNA Design	Deep learning models predicting sgRNA specificity and efficiency	Eliminate off-target editing in clinical use
Epigenome Editing	dCas9 fusions reversibly modulating gene expression without permanent DNA change	Reversible therapy for complex polygenic disease
Spatial Genomics	Mapping gene expression across tissue spatial coordinates	Cancer micro-environment therapy targeting
Metagenomics for Microbiome	Sequencing-based microbiome profiling for precision probiotics	Personalized gut-brain axis therapies
Digital Twins in Genomics	Patient-specific genomic-physiological computational models	Predict therapy response before administration
Pangenome Reference	Multi-ancestry genome reference replacing single-reference bias	Equitable global precision medicine

Source: Authors' analysis based on NIH All of Us Research Program (2023), Nature Biotechnology (2023)

a) In Vivo CRISPR Delivery

Expanding to in vivo delivery- injecting CRISPR components directly into the patient- requires efficient, cell-type-specific delivery vehicles. Lipid nanoparticles (LNPs), the delivery technology validated for mRNA COVID-19 vaccines, are now being adapted for CRISPR-Cas9 delivery to the liver. Intellia Therapeutics reported the first clinical evidence of in vivo CRISPR editing in humans in 2021, achieving durable transthyretin reduction in patients with hereditary transthyretin amyloidosis after a single IV infusion.

b) Pangenome Reference and Genomic Equity

The T2T (Telomere-to-Telomere) Consortium and Human Pangenome Reference Consortium (HPRC) are developing a pangenome reference that represents the genomic diversity of all human populations, including previously unsequenced structural variation. This advance will be foundational to achieving equitable precision medicine globally, particularly for populations underrepresented in current genomic databases.

13. Conclusion

This review highlights the transformative role of CRISPR-Cas9 and genomic technologies in advancing precision medicine. Evidence from recent clinical and translational studies demonstrates their potential to enable targeted diagnosis, personalized therapy, and curative interventions for genetic and complex diseases. Technologies such as next-generation sequencing, base editing, and pharmacogenomics further strengthen this paradigm shift. However, challenges including off-target effects, ethical concerns, regulatory uncertainty, and unequal data representation remain significant. Addressing these issues through improved validation, inclusive genomic databases, and clear clinical guidelines will be essential. Overall, genomic medicine is progressing toward a more predictive and individualized healthcare model with substantial future impact.

References

[1] Jinek, M., Chylinski, K., Fonfara, I., et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821.
[2] Cong, L., Ran, F.A., Cox, D., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823.
[3] Frangoul, H., Altshuler, D., Cappellini, M.D., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. New England Journal of Medicine, 384(3), 252–260.
[4] Stadtmauer, E.A., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481), eaba7365.
[5] Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149–157.
[6] Choi, J., et al. (2022). AI-guided CRISPR design for improved on-target efficiency. Nature Biotechnology, 40, 972–979.
[7] Ginsburg, G.S., & Phillips, K.A. (2018). Precision medicine: From science to value. Health Affairs, 37(5), 694–701.
[8] Komor, A.C., Kim, Y.B., Packer, M.S., et al. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420–424.
[9] Doudna, J.A., & Charpentier, E. (2012). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
[10] GRAIL Inc. (2022). PATHFINDER study: Multi-cancer early detection with Galleri. Annals of Oncology, 33(S7), S808.
[11] Reinert, T., et al. (2022). Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncology, 8(8), 1172–1181.
[12] Gootenberg, J.S., et al. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438–442.
[13] Gillmore, J.D., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502.
[14] Human Pangenome Reference Consortium (2023). A draft human pangenome reference. Nature, 617(7960), 312–324.
[15] Lander, E.S., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921.

[16] Dixit, A., et al. (2022). Landscape of somatic mutations across cancer types from whole-genome and whole-exome sequencing. Cell Reports Medicine, 3(4), 100569.
[17] Whirl-Carrillo, M., et al. (2021). An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 110(3), 563–572.
[18] Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589.
[19] Topol, E.J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
[20] DiMasi, J.A., Grabowski, H.G., & Hansen, R.W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.